
    
      This study is a 1:1:1 randomized, double-blinded, controlled phase Ⅳ clinical trial in a
      military command in Beijing. Healthy individuals aged between 18～34 years who had not
      received any influenza vaccine during recent three years will be enrolled and administrated
      one dose TIV. Safety data will be collected for whole study (Day 0 to Day 30).Blood samples
      will be collected for immunogenicity assessments before injection and 21 days after
      vaccination.
    
  